Forsta AP Fonden Acquires 5,800 Shares of Becton, Dickinson and Company (NYSE:BDX)

Forsta AP Fonden grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 11.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 56,000 shares of the medical instruments supplier’s stock after purchasing an additional 5,800 shares during the period. Forsta AP Fonden’s holdings in Becton, Dickinson and Company were worth $13,502,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of BDX. Kingswood Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $229,000. Vicus Capital acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $601,000. Red Door Wealth Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.7% during the 1st quarter. Red Door Wealth Management LLC now owns 1,437 shares of the medical instruments supplier’s stock valued at $356,000 after acquiring an additional 51 shares in the last quarter. BKM Wealth Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 17.1% during the 1st quarter. BKM Wealth Management LLC now owns 4,891 shares of the medical instruments supplier’s stock valued at $1,210,000 after acquiring an additional 715 shares in the last quarter. Finally, Claro Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 26.5% during the 1st quarter. Claro Advisors LLC now owns 2,852 shares of the medical instruments supplier’s stock valued at $706,000 after acquiring an additional 597 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on BDX. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $238.13 on Friday. The stock has a 50-day moving average price of $237.46 and a 200-day moving average price of $235.08. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.92. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market cap of $68.82 billion, a PE ratio of 52.45, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same period last year, the company posted $2.96 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.